ARS PHARMACEUTICALS INC(SPRY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SPRY ARS PHARMACEUTICALS INC

Market Closed 12-19 16:00:00 EST

10.49

+0.67

+6.82%

盘后10.53

+0.04+0.38%

19:56 EST

High10.99	Low9.80	Vol2.87M
Open9.84	D1 Closing9.82	Amplitude12.12%
Mkt Cap1.04B	Tradable Cap579.79M	Total Shares98.85M
T/O30.19M	T/O Rate5.19%	Tradable Shares55.27M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SPRY","market":"US","secType":"STK","nameCN":"ARS PHARMACEUTICALS INC","latestPrice":10.49,"timestamp":1766178000000,"preClose":9.82,"halted":0,"volume":2867270,"hourTrading":{"tag":"盘后","latestPrice":10.53,"preClose":10.49,"latestTime":"19:56 EST","volume":167951,"amount":1761834.5965,"timestamp":1766192189292},"delay":0,"floatShares":55270496,"shares":98848611,"eps":-0.81541,"marketStatus":"Market Closed","change":0.67,"latestTime":"12-19 16:00:00 EST","open":9.84,"high":10.99,"low":9.8,"amount":30189050.00496,"amplitude":0.121181,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.81541,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766394000000},"marketStatusCode":7,"adr":0,"listingDate":1607058000000,"exchange":"NASDAQ","adjPreClose":9.82,"preHourTrading":{"tag":"盘前","latestPrice":10.15,"preClose":9.82,"latestTime":"09:26 EST","volume":1018,"amount":10205.401136,"timestamp":1766154373387},"postHourTrading":{"tag":"盘后","latestPrice":10.53,"preClose":10.49,"latestTime":"19:56 EST","volume":167951,"amount":1761834.5965,"timestamp":1766192189292},"volumeRatio":1.8711113003474196,"impliedVol":0.8855,"impliedVolPercentile":0.688},"requestUrl":"/m/hq/s/SPRY/tweets","defaultTab":"tweets","newsList":[{"id":"2583068007","title":"ARS Pharmaceuticals Chief Business Officer Justin Chakma Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2583068007","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583068007?lang=en_us&edition=fundamental","pubTime":"2025-11-15 07:43","pubTimestamp":1763163801,"startTime":"0","endTime":"0","summary":"Justin Chakma, Chief Business Officer of ARS Pharmaceuticals Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ARS Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL1Z85Gr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"ARS Pharmaceuticals Chief Business Officer Justin Chakma Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2583208509","title":"ARS Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $25 From $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2583208509","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583208509?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:33","pubTimestamp":1763127184,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nFWN3WQ0Z3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"1189977586","title":"Stock Track | ARS Pharmaceuticals Surges 7.34% Pre-Market on Strong Q3 Revenue, Despite Wider Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=1189977586","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189977586?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:38","pubTimestamp":1762778319,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc. (NASDAQ: SPRY) saw its stock soar 7.34% in pre-market trading on Monday following the release of its third-quarter 2025 financial results. The biopharmaceutical company,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"1113100917","title":"Stock Track | ARS Pharmaceuticals Soars 7.34% Pre-Market on Strong Q3 Results and neffy Sales Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1113100917","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113100917?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:38","pubTimestamp":1762778304,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc. (NASDAQ: SPRY) stock surged 7.34% in pre-market trading on Monday following the release of its third-quarter 2025 financial results, which showcased strong revenue growth and...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"2582982031","title":"Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q3 Net Loss $0.52 a Share, vs. FactSet Est of $0.43 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2582982031","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582982031?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:11","pubTimestamp":1762773110,"startTime":"0","endTime":"0","summary":"Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q3 Net Loss $0.52 a Share, vs. FactSet Est of $0.43 Loss","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2582827210","title":"ARS Pharmaceuticals Q3 EPS $(0.52) Misses $(0.47) Estimate, Sales $32.501M Beat $28.743M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582827210","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582827210?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:00","pubTimestamp":1762772450,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.47) by 10.17 percent. This is a 160 percent decrease over losses of $(0.20) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48746889/ars-pharmaceuticals-q3-eps-0-52-misses-0-47-estimate-sales-32-501m-beat-28-743m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2582449827","title":"ARS Pharmaceuticals Q3 Net Income USD -51.151 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582449827","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582449827?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:00","pubTimestamp":1762772402,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nPLX59838A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2582827267","title":"ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights  for Neffy® (Epinephrine Nasal Spray)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582827267","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582827267?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:00","pubTimestamp":1762772401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nTUA6TWGML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2582827905","title":"Press Release: ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy(R) (epinephrine nasal spray)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582827905","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582827905?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:00","pubTimestamp":1762772400,"startTime":"0","endTime":"0","summary":"$32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of 2025. Continued U.S. product growth driven by direct-to-consumer  investments and real-world evidence, expected to accelerate with seamless prescribing experience. Strong balance sheet of $288.2 million cash, cash equivalents and short-term investments anticipated to fund operations through cash-flow break-even. \"We are executing our commercial strategy across multiple fronts, with each element reinforcing the others to drive momentum,\" said Richard Lowenthal, Co-Founder, President and CEO of ARS Pharma. \"Our direct-to-consumer campaigns are generating measurable increases in patient awareness; real-world evidence data are further strengthening prescriber confidence in neffy's effectiveness; and we are implementing advertising programs such as a free virtual prescriber option and zero dollar co-pay to further reduce barriers for patients, so that when healthcare providers want their ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4500","BK4139","BK4081","BK4203","BK4225","ALK","HCP","R","BK4588","BK4023","BK4008","BK4232","BK4585","NHI","EMA","BK4022","SPRY"],"gpt_icon":0},{"id":"2580373141","title":"ARS Pharma Launches GET Neffy® on US for Patients With Severe Allergic Reactions to Improve Access to Neffy (Epinephrine Nasal Spray)","url":"https://stock-news.laohu8.com/highlight/detail?id=2580373141","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580373141?lang=en_us&edition=fundamental","pubTime":"2025-11-04 21:00","pubTimestamp":1762261210,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nTUA3HTWV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2580731792","title":"ARS Pharmaceuticals resumed with a Buy at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2580731792","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580731792?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:55","pubTimestamp":1762260928,"startTime":"0","endTime":"0","summary":"Roth Capital analyst Kyle Bauser resumed coverage of ARS Pharmaceuticals (SPRY) with a Buy rating and $30 price target The firm is anticipating sig...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ars-pharmaceuticals-resumed-with-a-buy-at-roth-capital-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ars-pharmaceuticals-resumed-with-a-buy-at-roth-capital-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2580421351","title":"ARS Pharmaceuticals Inc. to Release Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2580421351","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580421351?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:01","pubTimestamp":1762174880,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc. will host a conference call and webcast to discuss its third quarter 2025 financial results on November 10, 2025. Results will be released on the Events & Presentations page in the Investors & Media section of the Company's website. A replay of the webcast will be available for 30 days following the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ARS Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on November 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL2yQZYq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4585","LU2210149790.SGD","BK4588","SPRY","IE00B64PRP62.GBP","LU2210150020.SGD","BK4139","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","NDAQ","IE00BKPKM429.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2580218948","title":"ARS Pharmaceuticals Reports Real-World Success of Intranasal Epinephrine neffy in Treating Anaphylaxis","url":"https://stock-news.laohu8.com/highlight/detail?id=2580218948","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580218948?lang=en_us&edition=fundamental","pubTime":"2025-11-03 20:45","pubTimestamp":1762173913,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc. has announced that it will present new real-world data on its intranasal epinephrine spray, neffy, at the 2025 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology , scheduled for November 6-10, 2025, in Orlando, FL. The presentations will include one late-breaking oral abstract and six poster presentations. According to the company, the oral presentation will report that approximately 9 out of 10 patients experiencing anaphylaxis were effectively treated with a single dose of neffy. Additionally, case reports will detail the use of neffy in patients undergoing oral food challenges or allergy immunotherapy, including instances where patients presented with nasal congestion or rhinorrhea as part of their anaphylactic reaction. These results will be presented at the upcoming ACAAI meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL7jtVS7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4585","BK4588","IE00BGHQF748.EUR","BK4139","SPRY","LU2210149790.SGD","BK4112","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0314104364.USD","LU2095319765.USD","LU2210150020.SGD","NDAQ"],"gpt_icon":0},{"id":"2573892378","title":"ARS Pharmaceuticals Says European Patent Office Upholds Nasal Spray Epinephrine Patent","url":"https://stock-news.laohu8.com/highlight/detail?id=2573892378","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573892378?lang=en_us&edition=fundamental","pubTime":"2025-10-08 20:31","pubTimestamp":1759926713,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals  said Wednesday that the European Patent Office has upheld all claims in one of its key patents related to its nasal epinephrine spray, covering formulations that include ingredients like Intravail.The company said the patent is valid in over 30 European countries and protects the product through at least 2039.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2573923208","title":"European Patent Office Upholds ARS Patent for Nasal Spray to Treat Allergic Reaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2573923208","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573923208?lang=en_us&edition=fundamental","pubTime":"2025-10-08 20:30","pubTimestamp":1759926600,"startTime":"0","endTime":"0","summary":"The European Patent Office upheld ARS Pharmaceuticals' novel claims in its patent for an epinephrine nasal spray to treat allergic reactions, the company said.ARS said its global intellectual property related to the nasal spray, called neffy, provides coverage until at least 2039.Earlier this year, the U.S. Patent and Trademark Office upheld a similar ARS patent following an independent challenge.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2573492804","title":"BRIEF-ARS Pharmaceuticals Receives Favorable Decision From European Patent Office On Patent Related To Neffy® (Epinephrine Nasal Spray)","url":"https://stock-news.laohu8.com/highlight/detail?id=2573492804","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573492804?lang=en_us&edition=fundamental","pubTime":"2025-10-08 20:10","pubTimestamp":1759925422,"startTime":"0","endTime":"0","summary":"BRIEF-ARS Pharmaceuticals Receives Favorable Decision From European Patent Office On Patent Related To Neffy (Epinephrine Nasal Spray)Oct 8 (Reuters) - ARS Pharmaceuticals Inc SPRY.O:ARS PHARMACEUTICA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nFWN3VP1I1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2573928489","title":"ARS Pharmaceuticals : Global Intellectual Property Portfolio Related to Neffy Provides Coverage Until at Least 2039","url":"https://stock-news.laohu8.com/highlight/detail?id=2573928489","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573928489?lang=en_us&edition=fundamental","pubTime":"2025-10-08 20:00","pubTimestamp":1759924846,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nFWN3VP1I1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2571350848","title":"ARS Pharmaceuticals Secures Up to $250 Million Loan Facility from RA Capital and OMERS Life Sciences to Accelerate neffy® Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2571350848","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571350848?lang=en_us&edition=fundamental","pubTime":"2025-09-30 04:05","pubTimestamp":1759176320,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Secures Up to $250 Million Loan Facility from RA Capital and OMERS Life Sciences to Accelerate neffy Commercialization. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ARS Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on September 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDL24ZQ1k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU0314104364.USD","BK4139","IE00B3QW5Z07.USD","SPRY","IE00BKPKM429.USD","BK4588","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","LU2210150020.SGD","NDAQ","LU2095319765.USD","BK4112"],"gpt_icon":0},{"id":"2571890350","title":"ARS Pharmaceuticals Secures up to $250 Million Loan Facility With Ra Capital Management and Omers Life Sciences to Accelerate U.S. Commercialization of Neffy®","url":"https://stock-news.laohu8.com/highlight/detail?id=2571890350","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571890350?lang=en_us&edition=fundamental","pubTime":"2025-09-30 04:05","pubTimestamp":1759176301,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nTUABCCW6S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2571508933","title":"ARS Pharmaceuticals Inc -  ARS Pharma Borrows Initial $100 Mln to Accelerate Neffy Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2571508933","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571508933?lang=en_us&edition=fundamental","pubTime":"2025-09-30 04:05","pubTimestamp":1759176301,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nTUABCCW6S:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ars-pharma.com","stockEarnings":[{"period":"1week","weight":0.0244},{"period":"1month","weight":0.4795},{"period":"3month","weight":0.0715},{"period":"6month","weight":-0.3361},{"period":"1year","weight":-0.0733},{"period":"ytd","weight":-0.0057}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including anaphylaxis. The company was founded in 2015 and is based in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.029887},{"month":2,"riseRate":0.6,"avgChangeRate":0.08605},{"month":3,"riseRate":0.4,"avgChangeRate":-0.024933},{"month":4,"riseRate":0.2,"avgChangeRate":-0.083829},{"month":5,"riseRate":0.8,"avgChangeRate":0.021109},{"month":6,"riseRate":0.6,"avgChangeRate":0.093442},{"month":7,"riseRate":0.8,"avgChangeRate":0.11695},{"month":8,"riseRate":0.4,"avgChangeRate":-0.080641},{"month":9,"riseRate":0.2,"avgChangeRate":-0.212128},{"month":10,"riseRate":0.4,"avgChangeRate":-0.021216},{"month":11,"riseRate":0.4,"avgChangeRate":0.043601},{"month":12,"riseRate":0.6,"avgChangeRate":0.055999}],"exchange":"NASDAQ","name":"ARS PHARMACEUTICALS INC","nameEN":"ARS PHARMACEUTICALS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ARS PHARMACEUTICALS INC(SPRY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ARS PHARMACEUTICALS INC(SPRY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ARS PHARMACEUTICALS INC,SPRY,ARS PHARMACEUTICALS INC股票,ARS PHARMACEUTICALS INC股票老虎,ARS PHARMACEUTICALS INC股票老虎国际,ARS PHARMACEUTICALS INC行情,ARS PHARMACEUTICALS INC股票行情,ARS PHARMACEUTICALS INC股价,ARS PHARMACEUTICALS INC股市,ARS PHARMACEUTICALS INC股票价格,ARS PHARMACEUTICALS INC股票交易,ARS PHARMACEUTICALS INC股票购买,ARS PHARMACEUTICALS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ARS PHARMACEUTICALS INC(SPRY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ARS PHARMACEUTICALS INC(SPRY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction